Consultant-Needed-Insert
X

Find Clinical Drug Pipeline Developments & Deals for Enzalutamide

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Enzalutamide,Androgen deprivation therapy

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Astellas Pharma

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 29, 2020

            Details:

            Phase 3 PROSPER trial evaluating XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) vs placebo plus ADT in men with non-metastatic castration-resistant prostate cancer, revealed that XTANDI plus ADT reduced the risk of death by 27% compared to placebo plus ADT.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): EPI-7386,Enzalutamide

            Therapeutic Area: Oncology Product Name: EPI-7386

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 22, 2020

            Details:

            The study highlighted full-length AR target engagement by EPI-7386, Its In vitro cellular gene expression analyses, Toxicology studies evaluating the safety profile of EPI-7386 and its starting clinical dose.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ORC-101,Enzalutamide

            Therapeutic Area: Oncology Product Name: ORC-101

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 22, 2020

            Details:

            ORIC-101 overcame GR-mediated resistance to chemotherapeutic agents including taxanes, antimetabolites and platinums, in both in vitro and in vivo efficacy studies spanning a variety of solid tumor types.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): KPG-121,Enzalutamide

            Therapeutic Area: Oncology Product Name: KPG-121

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 17, 2020

            Details:

            Two posters highlighting preclinical data of the company's lead drug candidates, KPG-121 and KPG-818, will be presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Enzalutamide

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 29, 2020

            Details:

            With this approval, XTANDI is now indicated for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC), a form of prostate cancer that has spread to other parts of the body and still responds to a medical or surgical treatment that lowers testosterone.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Atezolizumab,Enzalutamide

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 27, 2020

            Details:

            Roche conceded that Tecentriq failed to help prostate cancer patients live longer when added to Xtandi, Pfizer and Astellas’ mainstay androgen receptor antagonist.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ORC-101,Enzalutamide

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: J.P. Morgan

            Deal Size: $120.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering April 23, 2020

            Details:

            The IPO proceeds will push ORIC Pharma's lead program through phase 1b and into phase 2 and move its second program into the clinic.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ORC-101,Enzalutamide

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: J.P. Morgan

            Deal Size: $75.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering April 20, 2020

            Details:

            The funding is directed towards company's advancing pipeline of drug candidates for the treatment of prostate cancer and solid tumors.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Enzalutamide,Androgen deprivation therapy

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 11, 2020

            Details:

            The results demonstrated a statistically significant improvement in OS in patients with nmCRPC who were treated with XTANDI plus ADT.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ORIC-101,Enzalutamide

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 27, 2020

            Details:

            Study based on preclinical evidence suggesting ORIC-101, may inhibit a potential mechanism of resistance to XTANDI® in patients with metastatic prostate cancer.